FDA approves the first treatment for nasopharyngeal carcinoma, a rare cancer that originates in the nasopharynx. The drug (toripalimab-tpzi) is a next-generation, programmed death receptor-1 monoclonal antibody. Because of the tumor’s location (behind the nose), surgery is not usually an option.
Added on October 31st, 2023 by | Report Post
Leave A Comment
Subscribe
Login
Please login to comment
0 Comments
Oldest
